Translate page

  • Elza Lomaia - Management of CML: Treatment and side effects

  • John Goldman: CML Treatment with imatinib

  • Timothy Hughes - Optimising response and managing resistance to treatment

    The 2010 Rowley Prize is awarded to Dr. Moshe Talpaz

    The winner of the Rowley Prize for 2010 is MD Moshe Talpaz, awarded at the start of moshe talpazthe ESH-iCMLf meeting in September 2010 in Washington DC. Dr Janet Rowley has kindly given the iCMLf permission to name this award in her honour. Dr Moshe Talpaz is Associate Chief of the Division of Hematology/Oncology at the University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA. He is one of the leading clinical investigators in hematologic malignancies worldwide.

    Dr Talpaz' focus is on the treatment of chronic myelogenous leukemia (CML) and brings special expertise in immunotherapy, cytokines and biologic response modifiers. Internationally known for his role in the development of targeted cancer therapeutics, Dr Talpaz pioneered the study of interferon in CML, which was the first line therapy for CML until the introduction of STI571 (Imatinib, Gleevec). As a pivotal member of the team that developed Gleevec, Dr Talpaz was instrumental in bringing the new CML treatment to the market. As a leader in the development of novel therapeutics, Dr Talpaz has unique experience in the building of early Phase clinical trial programs. Dr Talpaz joined the University of Michigan Comprehensive Cancer Center in 2006, from M.D. Anderson Cancer Center in Houston, where he was professor of medicine and held the David Bruton Chair for Cancer Research. He has authored or co-authored nearly 400 articles in top national journals and textbooks, and is a member of the American Society of Hematology and the NCCN Chronic Myelogenous Leukemia Guidelines Panel.